Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review discusses 5-alpha reductase inhibitors, highlighting their long-term efficacy and tolerability in treating benign prostate hyperplasia, while also noting sexual dysfunction as a common adverse effect.

Finasteride safely treats enlarged prostate and male-pattern baldness.

This article describes the use, action, and considerations for 5-alpha-reductase inhibitors in treating benign prostatic hyperplasia and androgenic alopecia but provides no new clinical results, emphasizing existing knowledge and guidelines for healthcare providers.

Finasteride reduces certain behaviors caused by D1-like receptor agonists but not by D2-like receptor agonists in mice.

This study identified mutations in the FGF5 gene as a cause of extreme eyelash growth in Pakistani families, highlighting a potential target for regulating eyelash growth.

This review evaluates the use of 5α-reductase inhibitors in feminising hormone therapy, finding their additive feminising benefits unclear due to their specific action on testosterone conversion, with concerns highlighted regarding limited supporting evidence and safety signals, particularly for psychiatric and sexual effects.

This article reviews the role and controversies of 5α-reductase inhibitors like finasteride and dutasteride in managing prostate cancer, without presenting new research results.

This review highlights available treatments for frontal fibrosing alopecia, noting that 5-alpha reductase inhibitors, intralesional steroids, and hydroxychloroquine currently have the most evidence supporting their use, while other treatments show variable results and require further study.

This study found that in animal models of Tourette syndrome, stress-induced tic-like behaviors and sensorimotor gating deficits were reduced by finasteride, suggesting a role for neurosteroids like allopregnanolone.

Human growth factor 20 can boost mouse whisker growth.

This study found that finasteride treatment may decrease contraction of seminal vesicle tissue and alter some semen parameters in male rabbits.

This review concluded that 5α-reductase inhibitors like finasteride and dutasteride offer limited additional feminising effects in hormone therapy for transfeminine individuals, with the clearest use being androgenetic alopecia treatment; more research is needed for other potential benefits.

This study found that a mutant form of the FGF5s protein, FGF5sC93S, significantly increased hair count after 24 weeks of application on human scalps, suggesting its potential as a hair growth treatment.

This study reported that while no synthesized compounds surpassed finasteride in 5α-reductase inhibitory activity, certain 4-azasteroid-2-oximes exhibited notable inhibition.

PP405 may help hair growth by activating hair follicle stem cells.

This article reviews the biochemical properties of 5 alpha-reductase isoforms and highlights the limited dermatological use of inhibitors like finasteride, especially for type 1 isozyme-targeting agents, while suggesting further clinical exploration.

This abstract introduces the concept of follicular units (FUs) in the human scalp but presents no new research findings.

This study confirms that finasteride inhibits the conversion of testosterone to dihydrotestosterone in human dermal fibroblasts, suggesting potential therapeutic use for androgen-related skin disorders.

This study found that a 5-mer peptide called P5 promotes hair growth by activating adiponectin receptor 1, suggesting its potential use as a topical treatment for alopecia.

This study suggests that type I 5-alpha reductase may also play a role in hair growth, with dutasteride potentially being more potent than finasteride in modulating key hair growth gene expressions.

In this clinical experience, treating frontal fibrosing alopecia with oral finasteride, hydroxychloroquine, tacrolimus, and excimer laser was associated with optimal results in patients with active inflammation.

This article reviews the characteristics and uses of finasteride for benign prostatic hyperplasia, noting variable symptom improvement and ongoing investigation in other DHT-mediated conditions, and reports no new clinical results.

This historical review traces the discovery of 5-alpha reductase inhibitors, widely used in urology, from the study of guevedoces, Dominican children with a rare disorder leading to significant androgenization at puberty.

This review discusses advances in 5α-reductase inhibitors for treating male androgenetic alopecia and reports no new clinical results.

In this study, researchers found that the evolutionary and structural features of the oFGF5 gene in sheep may influence hair follicle development and hair growth regulation.

In this study, researchers successfully expressed recombinant human FGF5 protein in Arabidopsis, finding that this protein inhibits hair regeneration both in vitro and in vivo.

This study evaluated treatments for frontal fibrosing alopecia and found hydroxychloroquine and 5a-reductase inhibitors to be most effective, with 70-72% of patients experiencing stabilization or improvement, but limitations in treatment consistency and assessment methods remain.

This study found that the 5α-steroid metabolite profile in men with inherited 5α-reductase deficiency is similar to those taking the drug finasteride, suggesting the gene affects multiple steroid substrates.